Novo Nordisk Secures $2.6B Deal for Oral GLP-1/GIP Dual Agonist…

Event summary

Novo Nordisk licenses HRS-1596, a phase 1-ready oral GLP-1/GIP dual agonist, from Hengrui Pharma for $2.6B, including $300M upfront.
HRS-1596 is designed for once-weekly oral dosing, targeting obesity, type 2 diabetes, and other metabolic diseases.
Novo gains exclusive global rights (excluding China, Hong Kong, Macao, and Taiwan) to develop, manufacture, and commercialize HRS-1596.
The deal is subject to U.S. antitrust clearance and expected to close in Q4 2026.

The big picture

This deal underscores Novo Nordisk’s strategy to bolster its oral peptide pipeline, a key growth area in the treatment of metabolic diseases. The $2.6B agreement reflects the high stakes in developing next-generation therapies that offer convenience and efficacy. Hengrui Pharma’s expertise in innovation complements Novo’s global leadership in GLP-1 therapies, setting the stage for potential market disruption.

What we're watching

Pipeline Expansion: How Novo Nordisk integrates HRS-1596 into its existing portfolio of obesity and diabetes treatments.
Regulatory Approval: The pace at which HRS-1596 advances through clinical trials and secures regulatory approvals.
Market Competition: Whether HRS-1596 can differentiate itself in a crowded market of GLP-1-based therapies.